Myelodysplastic Syndromes

Oncology·MeSH: Myelodysplastic Syndromes

Prevalence

13.0 / 100K

Incidence

4.6 / 100K/yr

30 drugs in development·20 companies·47 clinical trials

Drug Pipeline by Phase

Approved(4)

Phase 3(10)

Drug	Company
elritercept	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
elritercept	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
elritercept (KER-050)	Keros Therapeutics, Inc. (KROS)
epoetin alfa	BRISTOL MYERS SQUIBB CO (BMY)
Erythropoiesis-stimulating agents	BRISTOL MYERS SQUIBB CO (BMY)
luspatercept	CELGENE CORP /DE/ (CELG)
Luspatercept	BRISTOL MYERS SQUIBB CO (BMY)
roxadustat	KYNTRA BIO INC. (KYNB)
tak-226	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-226	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(10)

Drug	Company
Elritercept	Merus N.V. (MRUS)
eltrombopag	Novartis AG (NVS)
Eltrombopag	Novartis AG (NVS)
imetelstat	HWH International Inc. (HWH)
incb000928	Incyte Corp. (INCY)
incb024360	GH Research PLC (GHRS)
luspatercept	GH Research PLC (GHRS)
oxi4503	Oncotelic Therapeutics, Inc. (OTLC)
TAK-226	Keros Therapeutics, Inc. (KROS)
Tebapivat	AGIOS PHARMACEUTICALS, INC. (AGIO)

Preclinical(1)

Drug	Company
rlyb332	Rallybio Corp (RLYB)

Unknown(2)

Drug	Company
hypomethylating agents	BRISTOL MYERS SQUIBB CO (BMY)
reb blood cell transfusion	BRISTOL MYERS SQUIBB CO (BMY)

Phase 1/Phase 2(3)

Drug	Company
allogeneic umbilical cord mesenchymal stem cells	Curative Biotechnology Inc (CUBT)
nkx101	Nkarta, Inc. (NKTX)
r906289 mono	RIGEL PHARMACEUTICALS INC (RIGL)

BioSniper tracks 30 drugs in development for Myelodysplastic Syndromes across 20 companies.

There are 47 clinical trials targeting Myelodysplastic Syndromes tracked by BioSniper.

The estimated prevalence of Myelodysplastic Syndromes is approximately 13.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.